logo BDSP

Base documentaire


  1. The safety of ranitidine in elderly versus non-elderly patients.

    Article - En anglais

    The authors conducted a retrospective review of 21 United States trials of ranitidine in acid peptic diseases and compared the adverse events in elderly (>=65 years)and nonelderly (<65 years) patients.

    Ranitidine dosages ranged from 150 mg/day to 300mg twice daily for treatment periods of 4 to 52 weeks.

    Of the 4041 patients included in this review, 402 elderly and 2188 nonelderly patients received ranitidine and 245 elderly and 1206 nonelderly patients received placebo; 29%, 29%, 32%, and 26% of these patients, respectively, reported some type of adverse event.

    Mots-clés Pascal : Ranitidine, Antiulcéreux, Antihistaminique, Récepteur histaminergique H2, Toxicité, Epidémiologie, Etats Unis, Amérique du Nord, Amérique, Etude longitudinale, Vieillard, Homme, Age

    Mots-clés Pascal anglais : Antiulcer agent, Antihistaminic, H2 receptor, Toxicity, Epidemiology, United States, North America, America, Follow up study, Elderly, Human, Age

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 93-0247370

    Code Inist : 002B02U08. Création : 199406.